Navin Fluorine Q1 FY27: consolidated PAT doubles YoY to ₹243 Cr, crushes Street estimates

Navin Fluorine's consolidated Q1 FY27 print is a clean beat: revenue from operations of ₹1,045.08 Cr grew 44.1% YoY (₹725.40 Cr) and 11.4% QoQ (₹937.71 Cr), while consolidated PAT of ₹243.31 Cr more than doubled YoY (+107.7% from ₹117.16 Cr) and rose 14.4% QoQ (₹212.62 Cr). Both land well above the ₹800-850 Cr revenue and ₹140-160 Cr PAT range our pre-result preview flagged as the on-plan expectation, and above the Street's broader 19-20% FY27 revenue-growth framework — this quarter alone ran more than double that pace. EPS (basic) came in at ₹47.45 versus ₹23.63 a year ago.

Unlike the year-ago and preceding quarters, Q1 FY27 carries no exceptional item on either statement — a clean quarter. That matters for reading the Q4 FY26 base used for QoQ comparison, which included a ₹13.72 Cr (consolidated) reversal of a New Labour Codes provision that flattered that quarter's reported numbers; QoQ growth, while still positive at 14.4% PAT and 11.4% revenue, is running against that inflated base rather than a clean one. On a YoY basis — the primary lens here — margins expanded meaningfully: consolidated OPM (EBITDA margin) rose to 34.17% from 28.51% a year ago, and NPM to 22.53% from 15.85%, both inside or above management's guided ~30% (+/-1-2%) FY27 EBITDA margin band. Sequentially OPM eased slightly from 35.71% in Q4, consistent with that quarter's one-off boost rather than any underlying softness.

The stock went into the print at ₹7,609.5, up 0.8% over the past month of trading.

For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 5 consecutive quarters; revenue is at a 6-quarter high.

Management's April guidance called for 'strong double-digit growth' in FY27 on the back of the AHF plant, the Chemours project and new HFC capacity, with CDMO and agrochemical visibility underpinning the outlook — this quarter's 44% YoY revenue growth and margin expansion are directionally consistent with that guide, though the company has not issued a formal quarter-specific number to grade against, and no management press release/MD&A commentary was available in this filing to quote directly. The standalone print is more moderate — revenue ₹694.68 Cr (+27.9% YoY) and PAT ₹190.64 Cr (+68.4% YoY) — a wide gap to the consolidated growth rate, pointing to the foreign CDMO subsidiaries (Manchester Organics, NFIL UK/USA, Navin Fluorine Shanghai) as the larger swing factor this quarter. Alongside the results, the Board approved ₹90 Cr of capex for Advanced Materials adoption capacity at Surat (commissioning targeted Q2 FY28, funded via internal accruals), following the July 30 DRDO partnership for sodium borohydride and a smaller ₹3.63 Cr captive-power SPV investment on July 27 — both consistent with the capex-heavy growth phase management flagged. Street positioning ahead of the print was constructive (27-analyst consensus, BUY-rated, price targets ₹7,316-7,372 versus ~₹7,580 spot), with the debate centred on whether the AHF/CDMO ramp justifies a 27x forward multiple against an 18-20x peer average — this quarter's numbers support that thesis rather than raising red flags.